Pathological Complete Response (PCR) with TDM1 (Trastuzumab Emtansine) in Refractory HER2-Positive Locally Advanced Breast Cancer (LABC)
- 6 Downloads
We report a patient with HER2-positive locally advanced breast cancer who progressed on neoadjuvant chemotherapy, chemoradiation and anti-HER2-based chemotherapy but achieved complete pathologic response with TDM1 (trastuzumab emtansine).
KeywordsTDM1 Pathologic complete response
Compliance with Ethical Standards
Conflict of interest
Authors declare that they have no conflict of interest.
- 1.Gianni L, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Lond Engl. 2010;375:377–84.CrossRefGoogle Scholar